NCT05485883View on ClinicalTrials.gov

Tislelizumab Plus Lenvatinib in Stage III-IV RCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Advanced Kidney Cancer
Interventions
DRUG

Tislelizumab Lenvatinib

Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects

Trial Locations (1)

300211

RECRUITING

Changyi Quan, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Second Hospital

OTHER